A Case of Recurrent Vogt-Koyanagi-Harada Disease Successfully Treated with Adalimumab in Young Female Adult Patient
Hyeon Yoon Kwon, Se Joon Woo
Korean J Ophthalmol. 2020;34(1):92-93.   Published online 2020 Feb 4     DOI: https://doi.org/10.3341/kjo.2019.0052
Citations to this article as recorded by Crossref logo
Immunosuppressive therapy for Vogt-Koyanagi-Harada disease: a retrospective study and review of literature
Najiha Rahman, Jose Carlo M Artiaga, Konstantinos Bouras, Joshua Luis, Angela Rees, Mark Westcott
Journal of Ophthalmic Inflammation and Infection.2023;[Epub]     CrossRef
Adalimumab in Vogt-Koyanagi-Harada Disease Refractory to Conventional Therapy
Shizhao Yang, Tianyu Tao, Zhaohao Huang, Xiuxing Liu, He Li, Lihui Xie, Feng Wen, Wei Chi, Wenru Su
Frontiers in Medicine.2022;[Epub]     CrossRef
Mechanisms, Pathophysiology and Current Immunomodulatory/Immunosuppressive Therapy of Non-Infectious and/or Immune-Mediated Choroiditis
Ioannis Papasavvas, Ilknur Tugal-Tutkun, Carl P. Herbort
Pharmaceuticals.2022; 15(4): 398.     CrossRef
Efficacy and Safety of Adalimumab for Exacerbation or Relapse of Ocular Inflammation in Patients with Vogt-Koyanagi-Harada Disease: A Multicenter Study
Shunsaku Nakai, Masaru Takeuchi, Yoshihiko Usui, Kenichi Namba, Kayo Suzuki, Yosuke Harada, Sentaro Kusuhara, Toshikatsu Kaburaki, Rie Tanaka, Masaki Takeuchi, Nobuhisa Mizuki, Kei Nakai, Hiroshi Goto, Carl P. Herbort
Ocular Immunology and Inflammation.2022; : 1.     CrossRef
Commentary: Treatment of refractory uveitis with Vogt Koyanagi Harada disease
Sivaraman Balamurugan, Somanath Anjana
Indian Journal of Ophthalmology - Case Reports.2022; 2(4): 909.     CrossRef